Tesaglitazar.
AstraZeneca plc is developing tesaglitazar, an oral dual peroxisome proliferator-activated receptor alpha/gamma agonist, for the potential improvement of dyslipidemia and glycemic control in type 2 diabetic patients.
Alkanesulfonates↗
Biomedical subjects
Niklaus Kamber
Publications and source records attributed to Niklaus Kamber.